Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ADRX vs ELAB: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ELAB Wins Head-to-Head Institutional Verdict (3–0 across 6 Pillars · 6–2 Matrix Metrics)

ELAB Overall Winner 6-Pillar Tally: ADRX 0 – 3 ELAB (3 Tie) Matrix Metrics: ADRX 2 – 6 ELAB

As of Nov 16, 2026, PMGC Holdings Inc. (ELAB) is the stronger overall head-to-head candidate over ADRX (ADRX) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 3–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ADRX carries a Unified Composite Score of 47.9/100 (HOLD) at $14.00 (N/M Forward P/E, N/A operating margin), whereas ELAB carries 53.0/100 (HOLD) at $1.66 (N/M Forward P/E, -470.0% operating margin).

  • Technical & Structure Timing Caution: ADRX trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A); meanwhile ELAB is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ADRX vs ELAB
ADRX US Equity
ADRX
Institutional Equity
$14.00
-1.41% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.05β · 76% Vol
Unified Composite Score
47.9 / 100 HOLD
Tech 50.0 Fund 50.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Trend telemetry aligned with daily close.
RSI-14: N/A · SMA20: N/A · SMA50: N/A
ELAB NASDAQ Head-to-Head Winner
PMGC Holdings Inc. Common Stock
Pharmaceutical Preparations
$1.66
+5.06% 1D
Market Cap $1.3M
TTM Revenue $2.6M
Forward P/E N/M
Beta / 30D Vol 5.47β · 94% Vol
Unified Composite Score
53.0 / 100 HOLD
Tech 60.0 Fund 50.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -14.2%), weak momentum, RSI 28
RSI-14: 28.0 · SMA20: $2.14 · SMA50: $3.19

6-Pillar Scorecard Institutional Category Breakdown (ADRX 0 – 3 ELAB)

Columns: Metric · ADRX · ELAB
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale ELAB
Revenue Growth (YoY) N/A -45.8%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) N/A $2.6M
Market Cap N/A $1.3M
3. Profitability & Quality ELAB
Gross Margin N/A -20.5%
Operating Margin N/A -470.0%
Net Profit Margin N/A 0.0%
Return on Equity (ROE) N/A -105.2%
4. Balance Sheet & Cash Flow ELAB
Cash Generation (TTM) N/A -$12M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE $3.9M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ADRX (2) vs ELAB (6)
Institutional Metric ADRX ELAB Criterion Row Edge
Market Capitalization
Scale
N/A $1.3M Larger Scale ELAB
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A -45.8% Higher Growth ELAB
Operating Margin (TTM)
Profitability
N/A -470.0% Higher Margin ELAB
Net Profit Margin
Profitability
N/A 0.0% Higher Margin ELAB
Return on Equity (ROE)
Capital Efficiency
N/A -105.2% Higher ROE ELAB
52-Week Range Position
Momentum
14% ($12–$23) 8% ($1–$14) Stronger Trend ADRX
Beta / 30D Volatility
Risk Regime
1.05β · 76% Vol 5.47β · 94% Vol Lower Realized Risk ADRX
Unified Institutional Score
Composite Signal
47.9 / 100 (HOLD) 53.0 / 100 (HOLD) Higher Composite ELAB
Trailing 12M Revenue (USD)
Operating Scale
N/A $2.6M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A -20.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) -$12M EBITDA ($3.9M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ADRX +19.39 pp
ADRX: -20.68% · ELAB: -40.07%
3M Horizon ADRX +36.03 pp
ADRX: -27.65% · ELAB: -63.68%
6M Horizon ADRX +36.03 pp
ADRX: -27.65% · ELAB: -63.68%
1Y Horizon ADRX +36.03 pp
ADRX: -27.65% · ELAB: -63.68%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ADRX vs ELAB. Trailing 12-month operating profitability (ADRX N/A vs ELAB -470.0%) and valuation multiples (ADRX N/M vs ELAB N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ADRX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
ELAB ADR TTM Benchmark FX-Normalized USD
TTM Revenue$2.6M
Gross Margin-20.5%
Op. Margin-470.0%
ROE / Fwd P/E-105.2% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ADRX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ADRX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ELAB UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ELAB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ADRX Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ELAB Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.3M market capitalization and -470.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ADRX vs ELAB Key Questions & Quantitative Answers

As of Nov 16, 2026, PMGC Holdings Inc. (ELAB) is the stronger overall head-to-head candidate over ADRX (ADRX) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 3–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ADRX carries a Unified Composite Score of 47.9/100 (HOLD) at $14.00 (N/M Forward P/E, N/A operating margin), whereas ELAB carries 53.0/100 (HOLD) at $1.66 (N/M Forward P/E, -470.0% operating margin). Technical & Structure Timing Caution: ADRX trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A); meanwhile ELAB is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ELAB leads the Growth & Scale pillar: ADRX posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with ELAB at -45.8% YoY revenue growth and +0.0% YoY earnings growth on $2.6M TTM revenue (-20.5% gross margin, -470.0% operating margin). On trailing 12-month operating scale, ADRX generates N/A in USD-normalized revenue versus $2.6M for ELAB. In operating R&D and SG&A reinvestment, ADRX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ELAB.

ADRX and ELAB trade at balanced relative valuation multiples. ADRX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas ELAB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ADRX (N/A ROE) versus ELAB (-105.2% ROE) capital efficiency.

In options market volatility and institutional positioning, ADRX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.05β · 76% Vol realized risk). By comparison, ELAB carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (5.47β · 94% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.